Neurodegenerative Diseases, Parkinson Disease
Conditions
Brief summary
Study AFF011 is a randomized controlled parallel Group phase I study to investigate the safety and tolerability of two doses of the vaccine AFFITOPE® PD03A given to patients with early Parkinson's disease. In total 36 patients will be enrolled in 3 independent groups (2 treatment groups, 1 Placebo group), each consisting of 12 patients. The patients will be randomized to either receive 15µg or 75µg AFFITOPE® PD03A formulated with adjuvant or the reference substance without active component (Placebo). Over a study duration of 52 weeks, the study participants receive 4 injections as basic immunization in a 4-weekly interval and 1 boost immunization 36 weeks after the first injection. Male and female patients aged 45 to 70 years can participate in the trial. 2 study sites in Austria (Innsbruck and Vienna) will be involved. AFF011 is part of a project SYMPATH funded by the European Commission (FP7-HEALTH-2013-INNOVATION-1 project; N° HEALTH-F4-2013-602999).
Interventions
BIOLOGICALLow dose AFFITOPE® PD03A + Adjuvant
s.c. injection
BIOLOGICALHigh dose AFFITOPE® PD03A + Adjuvant
s.c. injection
BIOLOGICALAdjuvant without active component
s.c. injection
Sponsors
PROSENEX AmbulatoriumbetriebsGMBH
Medical University Innsbruck
Forschungszentrum Juelich
Affiris AG
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
45 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Individuals with IPS diagnosed for less than 4 years and who present in Hoehn & Yahr Stages I/II and fulfill the United Kingdom Parkinson's Disease Society Brain Bank Criteria * The result of a DAT-SPECT and MRI examination of the patient's brain has to be consistent with the diagnosis of PD * Written Informed Consent Form signed and dated by the patient * Age between 45 and 70 * Female patients of childbearing potential are eligible if they use a medically accepted contraceptive method * A potential participant treated with conventional PD therapies must be on stable doses for at least 3 months prior to Visit 0 and during the entire trial period and must be a stable responder * Accepted PD medications include the following: levodopa (alone or in combination with benserazide, carbidopa), Catechol-O-methyltransferase inhibitors (entacapone, tolcapone), amantadine, non-ergot dopamine agonists (pramipexol, ropinirol, rotigotine), monoamine oxidase-B inhibitors (rasagiline, selegiline) and anticholinergic medication * A potential participant has to be on stable doses of all medications he/she is taking because of consisting illnesses according to medical history (except PD therapies, these will be recorded separately) for at least 30 days prior to Visit 0, if considered relevant by the PI * Upon PI's opinion, no visual or auditory impairments that would reduce the patients' ability to complete study questionnaires or be unable to receive instructions for these
Exclusion criteria
* Pregnant women * Sexually active women of childbearing potential who are not using a medically accepted birth control method throughout the study * Participation in another clinical trial within 3 months before Visit 0 * History of questionable compliance to visit schedule; patients not expected to complete the clinical trial * Presence or history of allergy to components of the vaccine, if considered relevant by the PI * Contraindication for MRI imaging such as metallic endoprosthesis or stent implantation in the last 6 months or allergy to MRI contrast agent * Contraindication for DAT-SPECT * Contraindication for lumbar puncture such as anticoagulation * Dementia * History and/or presence of autoimmune disease, if considered relevant by the PI * Recent (≤3 years since last specific treatment) history of cancer (Exceptions: basal cell carcinoma, intraepithelial cervical neoplasia) * Active infectious disease (e.g., Hepatitis B, C) * Presence and/or history of Immunodeficiency (e.g., HIV) * Significant systemic illness (e.g., chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, other deficiencies), if considered relevant by the PI * History of significant psychiatric illness such as schizophrenia, bipolar affective disorder or psychotic depression * Parkinson-like disease secondary to drug therapy side effects (e.g., due to exposure to medications that deplete dopamine \[reserpine, tetrabenazine\] or block dopamine receptors \[neuroleptics, antiemetics\] * Parkinson-plus syndromes (e.g. MSA, PSP) * Heredodegenerative disorders * Alcoholism or substance abuse within the past year (alcohol or drug intoxication) * Prior and/or current treatment with experimental immunotherapeutics including intravenous immunoglobulin * Prior and/or current treatment with immunosuppressive drugs * Change in dose of standard treatments for PD within 3 months prior to Visit 0 * Change in dose of previous and current medications which the patient is taking because of consisting illnesses according medical history (except PD therapies, these will be recorded separately) within the last 30 days prior to Visit 0, if clinically relevant * Treatment with deep brain stimulation * Venous status rendering it impossible to place an i.v. access * L-Dopa related motor complications (response fluctuations and/or dyskinesia) * Evidence for genetic forms of PD: leucine-rich repeat kinase 2 and Parkin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical significance/changes in laboratory parameters over time (study period) | 12 months | Laboratory assessment includes hematology, biochemistry, coagulation, serology and urinanalysis. |
| New findings or Change in pre-existing findings assessed in physical and neurological examinations over time (study period) | 12 months | — |
| Change in vital signs and Body mass over time (study period) | 12 months | The Evaluation of vital signs includes the changes in blood pressure, heart rate, respiratory rate and Body temperature over time (measured at each visit). |
| Safety related Evaluation of MRI results of patients' brain after visit 5 and visit 8 compared to baseline | 12 months | MRI safety measures will e.g. include the occurrence of inflammatory reactions (meningoencephalitis), new/changed hemorrhages and lacunar infarcts. |
| Number of patients who withdraw due to Adverse Events (AEs) | 12 months | The withdrawal criteria (continuation decision) in regards to the number of patients who withdraw due to AEs as well as the reason for withdrawal will be evaluated. |
| Occurrence of Adverse Events and Serious Adverse Events | 12 months | Evaluation of Adverse Events and Serious Adverse Events in regards to autoimmune reactions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in motor symptoms at visit 8 and visit 11 compared to baseline | 12 months | Change in motor symptoms: MDS Unified Parkinson's Disease Rating Scale (UPDRS) II and III |
| Change in non-motor symptoms at visit 8 and visit 11 compared to baseline | 12 months | Change in non-motor symptoms: PDQ-39 (Parkinson's Disease Quality of Life-39)/PD non-motor symptom score, MDS UPDRS I (Movement Disorder Society Unified Parkinson's Disease Rating scale), cognitive test battery, HAM-D (Hamilton Depression Rating Scale) |
| Immunological activity of AFFITOPE® vaccine PD03A | 12 months | Titer of vaccination induced antibodies directed towards vaccine components, alpha- and beta synuclein |
Countries
Austria
Outcome results
None listed